NCT04720976 - JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 23, 2021

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions

Solid TumorNSCLC

Interventions

DRUG

JAB-3312

JAB-3312 will be administered orally, variable dose.

DRUG

Binimetinib

Binimetinib will be administered orally.

DRUG

Pembrolizumab

Pembrolizumab will be administered as an intravenous infusion.

DRUG

Sotorasib

Sotorasib will be administered orally.

DRUG

Osimertinib

Osimertinib will be administered orally.

Trial Locations (15)

10016

Research Site, New York

32224

Research Site, Jacksonville

32763

Research Site, Orange City

46202

Research Site, Indianapolis

48202

Research Site, Detroit

55902

Research Site, Rochester

60637

Research Site, Chicago

63130

Research Site, St Louis

73104

Research Site, Oklahoma City

77030

Research Site, Houston

84112

Research Site, Salt Lake City

85054

Research Site, Phoenix

85259

Research Site, Scottsdale

90033

Research Site, Los Angeles

06510

Research Site, New Haven